FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Commission granted a marketing authorisation valid throughout the European Union for Evotaz on 13 July 2015.
Estonian: Euroopa Komisjon andis Evotazi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 13. juulil 2015.
English: A risk management plan has been developed to ensure that Evotaz is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Evotazi võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Evotaz?
Estonian: Mis meetmed võetakse, et tagada Evotazi ohutu ja efektiivne kasutamine?
English: Other information about Evotaz
Estonian: Muu teave Evotazi kohta
English: The full EPAR and risk management plan summary for Evotaz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Evotazi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: When the enzyme is blocked, the virus cannot reproduce itself and its spread in the body slows down.
Estonian: Kui ensüüm on blokeeritud, ei saa viirus paljuneda ning selle levik organismis aeglustub.
English: What is Evotaz and what is it used for?
Estonian: Mis on Evotaz ja milleks seda kasutatakse?
English: In addition, the use of atazanavir with cobicistat has been evaluated in one main study in 698 HIV patients who had not been treated previously.
Estonian: Peale selle hinnati atasanaviiri kasutamist koos kobitsistaadiga ühes põhiuuringus, milles osales 698 varem ravimata HIV-patsienti.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Evotaz's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Evotazi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Evotaz is available as tablets that contain 300 mg of atazanavir and 150 mg of cobicistat.
Estonian: Evotazi turustatakse tablettidena, mis sisaldavad 300 mg atasanaviiri ja 150 mg kobitsistaati.
English: Evotaz atazanavir / cobicistat
Estonian: Evotaz atasanaviir/kobitsistaat
English: The main measure of effectiveness was the proportion of patients in whom the HIV-1 count in the blood (known as viral load) was reduced to less than 50 copies/ml after 48 weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide protsent, kellel HIV-1 sisaldus veres (viiruskoormus) oli 48 ravinädala järel alla 50 koopia/ml.
English: This is a summary of the European public assessment report (EPAR) for Evotaz.
Estonian: See on ravimi Evotaz Euroopa avaliku hindamisaruande kokkuvõte.
English: Why is Evotaz approved?
Estonian: Miks Evotaz heaks kiideti?
English: It must also not be taken by patients taking certain medicines because of the possibility of interactions which could be harmful.
Estonian: Samuti ei tohi ravimit võimalike kahjulike koostoimete tõttu võtta patsiendid, kes kasutavad teatud muid ravimeid.
English: It is not intended to provide practical advice on how to use Evotaz.
Estonian: Hindamisaruandes ei anta Evotazi kasutamise praktilisi nõuandeid.
English: Evotaz can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infection.
Estonian: Evotaz on retseptiravim ja ravi peab alustama HIV-infektsiooni ravis kogenud arst.
English: Evotaz is an antiviral medicine used in combination with other medicines to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Evotaz on viirusevastane ravim, mida koos teiste ravimitega kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese I tüüpi immuunpuudulikkuse viiruse (HIV-1) infektsiooni raviks täiskasvanutel.
English: Evotaz's adverse effects were similar to those that occur with the individual medicines.
Estonian: Evotazi kõrvalnähud sarnanesid ravimite eraldi manustamise korral täheldatutega.
English: The most common side effects with Evotaz (which may affect more than 1 in 10 people) are jaundice, which may show as yellow discoloration of the eye, and nausea (feeling sick).
Estonian: Evotazi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on ikterus, mis võib avalduda silmavalgete kollasusena, ja iiveldus.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Evotaz, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Evotazi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What are the risks associated with Evotaz?
Estonian: Mis riskid Evotaziga kaasnevad?
English: The medicine is for use only in patients whose infection is not expected to be resistant to atazanavir.
Estonian: Ravimit tohib kasutada ainult patsientidel, kellel viirus eeldatavasti ei ole atasanaviiri suhtes resistentne.
English: Evotaz must not be taken by patients who have moderately or severely reduced liver function.
Estonian: Evotazi ei tohi kasutada maksatalitluse mõõduka või raske häirega patsiendid.
English: Combining atazanavir and cobicistat in a single tablet has the potential of simplifying the dosing regimen.
Estonian: Ühe tabletina manustatav atasanaviiri ja kobitsistaadi kombinatsioon võib lihtsustada annustamisskeemi.
English: For practical information about using Evotaz, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Evotazi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Cobicistat increases the level of atazanavir in the blood by slowing its breakdown.
Estonian: Kobitsistaat suurendab atasanaviiri sisaldust veres, aeglustades selle lagunemist.
English: Because atazanavir and cobicistat have both previously been shown to be effective and are authorised for use in the treatment of HIV infection, studies were mainly carried out to show that Evotaz produced similar levels of atazanavir in the blood to the two active substances given separately, and to atazanavir given with a different booster medicine, ritonavir (an established combination).
Estonian: Et nii atasanaviir kui ka kobitsistaat on mõlemad osutunud efektiivseks ja heaks kiidetud kasutamiseks HIV-infektsiooni ravis, oli uuringute peamine eesmärk tõendada, et Evotaz tekitab veres sarnase atasanaviiri sisalduse kui kummagi toimeaine manustamisel eraldi ning atasanaviiri manustamisel koos teise toimet võimendava ravimi ritonaviiriga (hästi tõestatud meditsiinilise kasutusega kombinatsioon).
English: Evotaz, taken with other HIV medicines, reduces HIV in the blood and keeps the virus at a low level.
Estonian: Koos teiste HIV-ravimitega manustatav Evotaz vähendab HIV-i kogust veres ja hoiab selle sisalduse väikese.
English: Atazanavir and cobicistat were compared with atazanavir and ritonavir; all patients also received the HIV medicines emtricitabine and tenofovir disoproxil.
Estonian: Atasanaviiri ja kobitsistaadi kombinatsiooni võrreldi atasanaviiri ja ritonaviiri kombinatsiooniga; kõik patsiendid said lisaks ka emtritsitabiini ja tenofoviirdisoproksiili (samuti HIV-ravimid).
English: This was comparable to a reduction in 87% of patients (304 of 348) treated with atazanavir and ritonavir.
Estonian: See oli võrreldav atasanaviiri ja ritonaviiriga ravitud patsientide tulemusega - 87% (304 patsienti 348st).
English: For more information about treatment with Evotaz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Evotaziga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Overall, 85% of patients (293 out of 344) treated with atazanavir and cobicistat achieved this reduction.
Estonian: See vähenemine oli toimunud 85% atasanaviiri ja kobitsistaadiga ravitud patsientidest (293 patsiendil 344st).
English: For the full list of all side effects reported with Evotaz, see the package leaflet.
Estonian: Evotazi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The active substances in Evotaz are already available in the EU as individual medicines: atazanavir is available as Reyataz and cobicistat as Tybost.
Estonian: Evotazi toimeaineid juba turustatakse Euroopa Liidus eraldi ravimitena: atasanaviiri turustatakse ravimina Reyataz ja kobitsistaati ravimina Tybost.
English: Evotaz contains two active substances: atazanavir and cobicistat.
Estonian: Evotaz sisaldab kahte toimeainet: atasanaviiri ja kobitsistaati.
English: How is Evotaz used?
Estonian: Kuidas Evotazi kasutatakse?
English: How does Evotaz work?
Estonian: Kuidas Evotaz toimib?
English: Atazanavir is a protease inhibitor.
Estonian: Atasanaviir on proteaasiinhibiitor, mis blokeerib HIV-ensüümi proteaasi.
English: Both active substances have already been shown to be effective and Evotaz may be a useful substitute for atazanavir accompanied by ritonavir as a booster.
Estonian: Mõlema toimeaine efektiivsus on tõendatud ning Evotaz võib olla atasanaviiri ja selle toimet võimendava ritonaviiri kombinatsioonravi kasulik asendusvariant.
English: What benefits of Evotaz have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Evotazi kasulikkus?
English: This therefore boosts atazanavir's antiviral effect.
Estonian: Seega võimendab kobitsistaat atasanaviiri viirusevastast toimet.
English: Evotaz contains the active substances atazanavir and cobicistat.
Estonian: Evotaz sisaldab toimeainetena atasanaviiri ja kobitsistaati.
English: The virus needs protease to make more viruses.
Estonian: Proteaas osaleb viiruse paljunemisel.
English: Subcutaneous use vial (glass)
Estonian: 150 mg süstelahuse pulber Subkutaanne viaal (klaas)
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled syringes (multipack)
Estonian: 6 (3 x 2) süstlit (hulgipakend)
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled pens (multipack)
Estonian: 6 (3 x 2) pen-süstlit (hulgipakend)
English: A risk management plan has been developed to ensure that Kovaltry is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Kovaltry võimalikult ohutu kasutamine.
English: The full EPAR and risk management plan summary for Kovaltry can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Kovaltry kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Kovaltry?
Estonian: Mis meetmed võetakse, et tagada Kovaltry ohutu ja efektiivne kasutamine?
English: Other information about Kovaltry
Estonian: Muu teave Kovaltry kohta
English: Kovaltry octocog alfa
Estonian: Kovaltry alfaoktokog
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Kovaltry's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Kovaltry kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Kovaltry approved?
Estonian: Miks Kovaltry heaks kiideti?
English: What is Kovaltry and what is it used for?
Estonian: Mis on Kovaltry ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Kovaltry.
Estonian: See on ravimi Kovaltry Euroopa avaliku hindamisaruande kokkuvõte.
English: Data from a supportive study also confirmed the benefits of preventative treatment with Kovaltry in reducing the number of bleeds.
Estonian: Ka toetava uuringu andmed kinnitasid profülaktilise Kovaltry-ravi kasu verejooksude arvu vähendamisel.
English: Hypersensitivity (allergic) reactions are uncommon with Kovaltry, affecting from 1 patient in 1,000 to less than 1 patient in 100.
Estonian: Ülitundlikkusreaktsioonid (allergiareaktsioonid) esinevad Kovaltry kasutamisel aeg-ajalt, 1 patsiendil 1000st kuni vähem kui 1 patsiendil 100st.
English: The dose and frequency of the injections depend on whether Kovaltry is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.
Estonian: Süstide annus ja manustamissagedus sõltuvad sellest, kas Kovaltryt kasutatakse verejooksude raviks või ennetamiseks, patsiendi VIII hüübimisfaktori vaeguse raskusastmest, verejooksu ulatusest ja asukohast ning patsiendi seisundist ja kehamassist.
English: The effectiveness of Kovaltry in preventing and treating bleeding has been shown in a main study involving 62 patients aged 12 years or older with severe haemophilia A who were previously treated with other factor VIII products.
Estonian: Kovaltry tõhusust verejooksude ennetamisel ja ravis näidati ühes põhiuuringus, kus osales 62 12aastast või vanemat raske A-hemofiiliaga patsienti, keda oli varem ravitud teiste VIII hüübimisfaktori preparaatidega.
English: What are the risks associated with Kovaltry?
Estonian: Mis riskid Kovaltryga kaasnevad?
English: A second study involved 51 children under 12 years of age previously treated with other factor VIII products, who also had 3.8 bleeds per year on average during treatment with Kovaltry (mostly related to injuries).
Estonian: Teises uuringus osales 51 alla 12aastast last, keda oli varem ravitud teiste VIII hüübimisfaktori preparaatidega ning kellel Kovaltry-ravi ajal oli samuti keskmiselt 3,8 verejooksu aastas (valdavalt seoses vigastustega).
English: It is not intended to provide practical advice on how to use Kovaltry.
Estonian: Hindamisaruandes ei anta Kovaltry kasutamise praktilisi nõuandeid.
English: Kovaltry has been shown to be effective in both preventing and treating bleeds, including managing blood loss during surgery, and can be used in all age groups.
Estonian: Kovaltry tõhusus verejooksude ennetamisel ja ravil, sealhulgas operatsiooniaegse verekaotuse ohjamisel, on tõestatud ning seda ravimit saab kasutada kõigis vanuserühmades.
English: For the full list of all side effects and restrictions with Kovaltry, see the package leaflet.
Estonian: Kovaltry kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The active substance in Kovaltry, octocog alfa, works in the body in the same way as human factor VIII.
Estonian: Kovaltry toimeaine alfaoktokog toimib organismis samamoodi nagu inimese VIII hüübimisfaktor.
English: In addition, the company that markets Kovaltry will complete studies to investigate the safety and efficacy of the medicine in patients who have not previously been treated with other factor VIII products, and to provide further evidence of the safety and efficacy of long-term treatment with Kovaltry in children.
Estonian: Peale selle viib Kovaltry turustaja lõpule uuringud, milles uuritakse selle ravimi ohutust ja tõhusust patsientidel, keda ei ole varem VIII hüübimisfaktori preparaatidega ravitud, ja uuringud, millest saadakse täiendavaid tõendeid Kovaltry pikaajalise ravi ohutuse ja tõhususe kohta lastel.
English: The number of bleeds that occurred during Kovaltry treatment was calculated as 3.8 bleeds per year on average (mostly into joints).
Estonian: Kovaltry-ravi ajal esinenud verejooksude arv oli keskmiselt 3,8 verejooksu aasta kohta (valdavalt liigestes).
English: Kovaltry is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of a clotting protein called factor VIII).
Estonian: Kovaltry on ravim, mida kasutatakse verejooksude raviks ja ennetamiseks A-hemofiiliaga (VIII hüübimisfaktori vaegusest tingitud pärilik hüübimishäire) patsientidel.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kovaltry, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Kovaltry omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For more information about treatment with Kovaltry, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Kovaltryga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Kovaltry, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Kovaltry kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How does Kovaltry work?
Estonian: Kuidas Kovaltry toimib?
English: What benefits of Kovaltry have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kovaltry kasulikkus?
English: How is Kovaltry used?
Estonian: Kuidas Kovaltryt kasutatakse?
English: About 70% of the bleeding events that occurred were managed with a single injection of Kovaltry, and about another 15% responded to a second injection; the response was considered good or excellent in around 80% of cases.
Estonian: Tekkinud verejooksudest ligikaudu 70% korral piisas raviks Kovaltry ühest süstist ja veel ligikaudu 15% reageeris teisele süstile.
English: This compared with an average of 6.9 bleeds per year before Kovaltry treatment.
Estonian: Enne Kovaltry-ravi alustamist oli keskmine verejooksude arv 6,9 verejooksu aasta kohta.
English: Kovaltry can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.
Estonian: Ravi peab toimuma hemofiilia ravis kogenud arsti järelevalve all.
English: Kovaltry is available as a powder and solvent used to make a solution for injection.
Estonian: Kovaltryt turustatakse süstelahuse pulbri ja lahustina.
English: All of the tablets must be taken together at the same time every day, at least 1 hour before or 1 hour after food.
Estonian: Kõik tabletid tuleb võtta korraga iga päev samal kellaajal ning vähemalt 1 tund enne või 1 tund pärast sööki.
English: What measures are being taken to ensure the safe and effective use of Tyverb?
Estonian: Mis meetmed võetakse, et tagada Tyverbi ohutu ja efektiivne kasutamine?
English: Tyverb (lapatinib)
Estonian: Tyverb (lapatiniib)
English: Further information on Tyverb can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Tyverbi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Tyverb
Estonian: Muu teave Tyverbi kohta
English: The European Medicines Agency decided that Tyverb's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Tyverbi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: What is Tyverb and what is it used for?
Estonian: Mis on Tyverb ja milleks seda kasutatakse?
English: The women had not received trastuzumab or an aromatase inhibitor before entering this study.
Estonian: Naised ei olnud enne uuringu alustamist kasutanud ei trastusumaabi ega aromataasiinhibiitorit.
English: This was switched to a full marketing authorisation on 17 February 2015.
Estonian: Tingimuslik müügiluba muudeti tavaliseks müügiloaks 17. veebruaril 2015.
English: This combination is used in women who do not currently need to receive standard chemotherapy to treat their cancer.
Estonian: Seda kombinatsiooni kasutatakse naistel, kelle vähi raviks ei ole hetkel vaja standardset keemiaravi.
English: This means that there was more evidence to come about the effectiveness of the medicine.
Estonian: See tähendab, et selle ravimi efektiivsuse toetuseks oodati veel täiendavaid andmeid.
English: As for all medicines, data on the use of Tyverb are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Tyverbi kasutamise kohta pidevat järelevalvet.
English: Tyverb received a conditional marketing authorisation valid throughout the EU on 10 June 2008.
Estonian: Tyverb on saanud müügiloa tingimusliku heakskiidu alusel, mis kehtib kogu ELis, 10. juunil 2008.
English: If patients start to take Tyverb again, they may need to use a lower dose.
Estonian: Kui patsiendid alustavad Tyverbi kasutamist uuesti, võib vaja olla kasutada väiksemat annust.
English: Patients who stop taking Tyverb after developing severe liver problems should not start to take the medicine again.
Estonian: Patsiendid, kes lõpetavad Tyverbi kasutamise pärast raskete maksaprobleemide tekkimist, ei tohi ravimit uuesti võtma hakata.
English: What are the risks associated with Tyverb?
Estonian: Mis riskid Tyverbiga kaasnevad?
English: The studies also looked at how long the patients survived.
Estonian: Uuringutes vaadeldi ka patsientide üldist elumust.
English: Tyverb is available as tablets (250 mg) and the recommended dose is 4 tablets a day when used with trastuzumab, 5 tablets a day when it is used with capecitabine, and 6 tablets a day when taken with an aromatase inhibitor.
Estonian: Tyverbit turustatakse tablettidena (250 mg) ning soovitatav annus on 4 tabletti ööpäevas kasutamisel koos trastusumaabiga, 5 tabletti ööpäevas kasutamisel koos kapetsitabiiniga ja 6 tabletti ööpäevas kasutamisel koos aromataasiinhibiitoriga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tyverb have also been included in the summary of product characteristics and the package leaflet.
Estonian: Tyverbi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: In all the studies, the main measure of effectiveness was how long the patients lived without their disease getting worse, which was assessed in scans.
Estonian: Kõigis uuringutes oli efektiivsuse põhinäitaja progresseerumiseta elumus (kui kaua patsiendid elasid haiguse süvenemiseta), mida hinnati piltdiagnostikaga.
English: For more information about using Tyverb, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Tyverbi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: ‘Advanced' means that the cancer has started to spread and ‘metastatic' means that the cancer has already spread to other parts of the body;
Estonian: „Kaugelearenenud“ tähendab, et vähk on hakanud organismis levima ka mujale, ja „metastaatiline“, et vähk on juba levinud organismis ka mujale.
English: Side effects reported with Tyverb are carefully evaluated and any necessary action taken to protect patients.
Estonian: Tyverbi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Tyverb is used in the following ways:
Estonian: Tyverbit kasutatakse järgmiselt.
English: Tyverb was originally given ‘conditional approval'.
Estonian: Tyverbi müügiluba anti esialgu tingimusliku heakskiidu alusel.
English: The most common side effects with Tyverb (which may affect more than 1 in 4 patients) are rash and side effects affecting the stomach and gut (such as diarrhoea, nausea (feeling sick) and vomiting).
Estonian: Tyverbi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 4st) on lööve ning mao ja soole kõrvalnähud (nt kõhulahtisus, iiveldus ja oksendamine).
English: How is Tyverb used?
Estonian: Kuidas Tyverbit kasutatakse?
English: How does Tyverb work?
Estonian: Kuidas Tyverb toimib?